Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Rezvani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a physician and clinical researcher at Stanford University, specializing in hematopoietic cell transplantation and cellular therapy.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Lewis Katz School of Medicine at Temple UniversityClass of 2001
Certifications & Licensure
CA State Medical License 2014 - 2027
WA State Medical License 2004 - 2015
NC State Medical License 2001 - 2004
Clinical Trials
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 2006 Dec 01
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2009 Feb 01
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsOmidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program.Mitchell E Horwitz, Gary J Schiller, Stephanie B Tsai, Andrew R Rezvani, Richard T Maziarz
Transplantation and Cellular Therapy. 2025-07-01 - Accurate prediction of absolute prokaryotic abundance from DNA concentration.Jakob Wirbel, Tessa M Andermann, Erin F Brooks, Lanya Evans, Adam Groth
Cell Reports Methods. 2025-05-19 - 3 citationsDonor regulatory T-cell therapy to prevent graft-versus-host disease.Everett H Meyer, Anna Pavlova, Alejandro Villar-Prados, Cameron Bader, Bryan Xie
Blood. 2025-05-01
Abstracts/Posters
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsAndrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...Andrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021- Nevada Cancer Survivor Found to Have Two Different Sets of DNA After Bone Marrow Transplant 4 Years AgoDecember 10th, 2019
- After Bone Marrow Transplant, Patient's Blood Contains Only Donor's DNA: Three Months After a Nevada Man Received a Bone Marrow Transplant, Tests Revealed the DNA in His Blood Had Been Replaced by the DNA of His Donor, a Man He Barely Knew, According t...December 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
